Artal Group’s Autolus Therapeutics AUTL Stock Holding History

Artal Group’s Portfolio AUTL Stock Details AUTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-285,000	Closed	-$3.32M	–	133
2020 Q3	$3.32M	Sell	285,000 -115,000	-29%	-$1.67M	0.08%	111
2020 Q2	$6.41M	Sell	400,000 -100,000	-20%	-$1.11M	0.18%	93
2020 Q1	$3M	Hold	500,000	–	–	0.13%	94
2019 Q4	$6.6M	Hold	500,000	–	–	0.26%	64
2019 Q3	$6.21M	Hold	500,000	–	–	0.25%	66
2019 Q2	$8.05M	Buy	500,000 +50,000	+11%	+$1.12M	0.33%	61
2019 Q1	$14.2M	Sell	450,000 -25,000	-5%	-$711K	0.58%	40
2018 Q4	$15.6M	Sell	475,000 -25,000	-5%	-$822K	0.58%	34
2018 Q3	$15.3M	Sell	500,000 -25,000	-5%	-$675K	0.4%	37
2018 Q2	$14.1M	Buy	+525,000	New	+$13.9M	0.3%	37

Other funds holding AUTL

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Artal Group's AUTL Position: Q4 2020 in Review

Artal Group sold out of Autolus Therapeutics (AUTL) in Q4 2020, closing a stake of 285,000 shares — an estimated $3.32M sold.

Artal Group first reported a position in AUTL in Q2 2018 and held it in 10 quarters. The position peaked at $15.6M in Q4 2018. 48 funds tracked by Wall St. Rank hold AUTL as of Q4 2020.

Artal Group reported no remaining Autolus Therapeutics position as of Q4 2020 after selling out during the quarter.
Artal Group sold 285,000 Autolus Therapeutics shares in Q4 2020, an estimated $3.32M.
Artal Group first reported a position in Autolus Therapeutics in Q2 2018 and held it in 10 quarters.
Artal Group's Autolus Therapeutics position peaked at $15.6M in Q4 2018.
48 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q4 2020.

Based on Artal Group's 13F filing for Q4 2020, filed 11 Feb 2021.